<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263948</url>
  </required_header>
  <id_info>
    <org_study_id>2017-12-033</org_study_id>
    <nct_id>NCT04263948</nct_id>
  </id_info>
  <brief_title>Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform</brief_title>
  <acronym>MULTIDOM</acronym>
  <official_title>Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Domomedecine Plateform</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faculty of Medicine Paris Saclay University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Altran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer is a rapidly developing cancer with a poor prognosis. The mFOLFIRINOX&#xD;
      protocol has become the standard medical treatment for this pathology. However, mFOLFIRINOX&#xD;
      is the cause of severe toxicities including leukoneutropenia, thrombocytopenia, diarrhea,&#xD;
      nausea-vomiting, anorexia, asthenia, weight loss and peripheral sensory neuropathy.&#xD;
      Therefore, its indication is limited to patients in good general condition. In practice, it&#xD;
      is often interrupted upon the occurrence of hematological and/or clinical grade 3-4&#xD;
      toxicities, Remote patient tele-monitoring of symptoms (Patient Reported Outcomes), body&#xD;
      weight, circadian rhythms, sleep and activity would allow the identification of early warning&#xD;
      signals reflecting deterioration or improvement in the health of these fragile patients, and&#xD;
      trigger proactive interventions, while they are outside the hospital. Thus, the MultiDom&#xD;
      study proposes a comprehensive tele-monitoring and telecare strategy that would complement&#xD;
      standard of care over a 7-weeks period to 42 consenting patients. The patients receive&#xD;
      neoadjuvant or first line chemotherapy with mFOLFIRINOX for advanced or metastatic pancreatic&#xD;
      cancer at one of four centres in Ile-de-France region (France).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MultiDom stands up among the very first prospective patient-entered and multidimensional,&#xD;
      multiactor and multicenter study, that assesses the qualitative and quantitative impact of&#xD;
      mFOLFIRINOX on the daily life of patients with pancreatic cancer in real time. Main endpoint&#xD;
      is the rate of patients undergoing toxicity-related emergency hospitalisations, and the&#xD;
      objective is to reduce it to &lt;10%. Telemonitored data-based proactive interventions will&#xD;
      expectedly prevent worsening of patients 'health, and maintain their chances of disease&#xD;
      control on effective mFOLFIRINOX chemotherapy.&#xD;
&#xD;
      Participating patients have usual follow up and treatments for their disease, but also: wear&#xD;
      a chest sensor that measures and teletransmits accelerometry, surface temperature and&#xD;
      3D-orientation every min, weigh themselves daily on a BLE-balance, with immediate weight tele&#xD;
      transmission, and fill out electronic PRO questionnaires daily using a telecommunicating&#xD;
      tablet.&#xD;
&#xD;
      All data are tele transmitted to an approved health data hub, and automatically analysed for&#xD;
      physical activity, sleep, circadian rhythms, symptoms scores trends in real time.&#xD;
      Visualization screens and alerts are generated according to preset thresholds, and medical&#xD;
      team responses are traced.&#xD;
&#xD;
      Currently recruiting centres:&#xD;
&#xD;
        1. Clinique du Mousseau, Evry, France&#xD;
&#xD;
        2. Hospital Paul Brousse (Assistance Publique-Hôpitaux de Paris), Villejuif, France&#xD;
&#xD;
        3. Clinique St-Jean L'Ermitage, Melun, France&#xD;
&#xD;
        4. Private Hospital of Antony, Antony, France&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity-related emergency hospitalisation rate</measure>
    <time_frame>First cycle of treatment of 6 weeks</time_frame>
    <description>The main objective is to assess the toxicities occurring during the 6 weeks following the start of the 1st cycle of FOLFIRINOX in conventional administration in patients benefiting from the PiCADo telemonitoring system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates and grades toxicity and early tumor responses</measure>
    <time_frame>First cycle of treatment of 6 weeks</time_frame>
    <description>Secondary objectives include rates and grades of toxicity and early tumor responses, as well as PiCADo platform performances and users perceptions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Picado Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patients undergo multidimensional tele monitoring for 7 weeks using an upgraded version of the Picado internet platform</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Picado system internet platform and connected objects</intervention_name>
    <description>The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.</description>
    <arm_group_label>Picado Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Histological or cytological diagnosis of pancreatic adenocarcinoma&#xD;
&#xD;
          -  Locally advanced or metastatic pancreatic cancer&#xD;
&#xD;
          -  With or without previous surgery (pancreas and / or metastases)&#xD;
&#xD;
          -  Performance status of 0 or 1 according to WHO&#xD;
&#xD;
          -  Age between 18 and 85 years old included&#xD;
&#xD;
          -  No history of prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  Absence of cutaneous or mucosal jaundice or skin pruritus&#xD;
&#xD;
          -  No proven thrombosis&#xD;
&#xD;
          -  Absence of heart disease or other pathology poorly controlled by current treatments&#xD;
&#xD;
          -  Bilirubinemia and alkaline phosphatases &lt;1.5 ULN (with or without stent)&#xD;
&#xD;
          -  Hematological, renal and hepatic laboratory tests authorizing the administration of&#xD;
             mFOLFIRINOX&#xD;
&#xD;
          -  Affiliated subject or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient who freely signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immediately resectable pancreatic cancer&#xD;
&#xD;
          -  No histological or cytological evidence of pancreatic adenocarcinoma&#xD;
&#xD;
          -  Performance status&gt; 1 (WHO)&#xD;
&#xD;
          -  Age &lt;18 and&gt; 85 years old&#xD;
&#xD;
          -  Prior administration of chemotherapy or radiotherapy&#xD;
&#xD;
          -  Skin jaundice and / or pruritus&#xD;
&#xD;
          -  Uncontrolled venous or arterial thrombosis&#xD;
&#xD;
          -  Co morbidity not controlled by a specific treatment&#xD;
&#xD;
          -  Biological anomalies contraindicating the administration of one or more drugs which&#xD;
             make up FOLFIRINOX&#xD;
&#xD;
          -  Lack of GPRS coverage in the home&#xD;
&#xD;
          -  Patient participating in another clinical study&#xD;
&#xD;
          -  Protected patient: adult under guardianship, curatorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Pregnant, lactating or parturient woman&#xD;
&#xD;
          -  Patient hospitalized without consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JEAN FRANÇOIS OUDET</last_name>
    <phone>0683346567</phone>
    <phone_ext>0683346567</phone_ext>
    <email>jeanfrancois.oudet@free.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Barba</last_name>
    <phone>+330664888704</phone>
    <phone_ext>+330664888704</phone_ext>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique du Mousseau</name>
      <address>
        <city>Évry</city>
        <state>IDF</state>
        <zip>91000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Francois OUDET</last_name>
      <phone>+33683346567</phone>
      <phone_ext>+33683346567</phone_ext>
      <email>jf.oudet@ecten.eu</email>
    </contact>
    <contact_backup>
      <last_name>Marie Barba</last_name>
      <phone>+330664888704</phone>
      <phone_ext>+330664888704</phone_ext>
      <email>mh.barba@ecten.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed BOUCHAHDA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francis LEVI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bouchahda M, Komarzynski S, Ulusakarya A, Attari A, Duprès A, Breda G, Fritsch A, Adam R, Lévi F (2020) Improving FOLFIRINOX safety in pancreatic cancer patients through multidimensional remote monitoring and proactive care using a domomedecine mobile platform. J Clin Oncol 38: TPS4673.</citation>
  </reference>
  <reference>
    <citation>Lévi F, Komarzynski S, Huang Q, Young T, Ang Y, Fuller C, Bolborea M, Brettschneider J, Fursse J, Finkenstädt B, White DP, Innominato P. Tele-Monitoring of Cancer Patients' Rhythms during Daily Life Identifies Actionable Determinants of Circadian and Sleep Disruption. Cancers (Basel). 2020 Jul 17;12(7). pii: E1938. doi: 10.3390/cancers12071938.</citation>
    <PMID>32708950</PMID>
  </reference>
  <reference>
    <citation>Innominato P, Komarzynski S, Karaboué A, Ulusakarya A, Bouchahda M, Haydar M, Bossevot-Desmaris R, Mocquery M, Plessis V, Lévi F. Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Study. JCO Clin Cancer Inform. 2018 Dec;2:1-15. doi: 10.1200/CCI.17.00125.</citation>
    <PMID>30652550</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreas cancer</keyword>
  <keyword>Plateform monitoring</keyword>
  <keyword>metastatic or &quot;borderline&quot;</keyword>
  <keyword>telemedicine</keyword>
  <keyword>tele monitoring</keyword>
  <keyword>telecare</keyword>
  <keyword>emergency hospitalisations</keyword>
  <keyword>patient-centered medicine</keyword>
  <keyword>internet platform</keyword>
  <keyword>circadian rhythms</keyword>
  <keyword>chronotherapy</keyword>
  <keyword>physical activity</keyword>
  <keyword>sleep</keyword>
  <keyword>patient -reported outcomes</keyword>
  <keyword>symptoms</keyword>
  <keyword>quality of life</keyword>
  <keyword>compliance</keyword>
  <keyword>sensors</keyword>
  <keyword>electronic questionnaires</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

